Aegros Ltd's John Manusu introduces viewers to Australia’s newest plasma fractionator, which is looking to hit the local bourse early next year in what Manusu says could be a multi-billion-dollar listing. The company's name, which is Latin for patient, reflects its ethos: to put people first as it develops a pipeline of safe, secure and sustainable therapeutic plasma products. In fact, Aegros’ first product is a COVID-19 hyperimmune called Covimmune, which can offer immediate passive immunity for frontline health workers and those unable to take vaccines. Looking ahead, the managing director speaks to Aegros' mission in a $20 billion global market and the company's commercialisation strategy.
Aegros talks therapeutic plasma and IPO plans
